Effect of Epalrestat on Heart Rate Variability in Patients with Diabetic Asymptomatic Myocardial Ischemia
- VernacularTitle:依帕司他对糖尿病无症状心肌缺血患者心率变异性的影响
- Author:
Jinfeng SHENG
- Publication Type:Journal Article
- Keywords:
Epalrestat;
Asymptomatic myocardial ischemia;
Diabetes;
Heart rate variability
- From:
China Pharmacist
2015;(1):110-112
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effect of epalrestat on the heart rate variability in diabetes patients with silent myocardial is-chemia. Methods:Totally 60 patients were randomly divided into the control group and the treatment group with 30 cases in each. The two groups were given insulin or other routine drugs to keep blood sugar under control, ARB or ACEI and CCB to bring high blood pres-sure down, and statins to regulate lipid and anti-platelet aggregation, and both groups were without the use of beta blockers. The treat-ment group was given epalrestat 50mg three times a day for 4 weeks additionally. The indices of FPG, 2hPG, HbA1c, SBP, DBP, T-CHOL, TG, HDL-C, LDL-C and heart rate variability were observed after the treatment. Results: Compared with those before the treatment, the values of FPG, 2HPG, HbA1C, SBP, DBP, T-CHOL and LDL-c were decreased after the treatment in the two groups, and the differences were statistically significant (P <0.05), while the differences between the two groups were not obvious(P >0. 05). After the treatment, SDNN, SDANN, SDNNI, RMSSD, PNN50 and Mean HR in the treatment group were obviously im-proved, which were better than those in the control group (P<0.05). The adverse reactions in the two groups were similar (P<0. 05). Conclusion:Epalrestat can significantly improve HRV-related indicators in the diabetes patients with silent myocardial ischemi-a, which can reduce the risk of sudden death without significant adverse reactions in the combination with other drugs.
